Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Abbott Laboratories (NYSE:ABT) stock fell on Thursday after the company reported fourth-quarter 2025 sales and the first-quarter 2026 earnings outlook below expectations.

Earnings Snapshot

The company reported quarterly sales of $11.46 billion, slightly missing the consensus of $11.80 billion.

Sales increased 4.4% on a reported basis, 3% on an organic basis, or 3.8% when excluding COVID-19 testing-related sales.

The U.S. MedTech giant reported adjusted earnings of $1.50, in line with Wall Street estimates.

“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future,” said Robert Ford, chairman and CEO, Abbott. “We’re well-positioned for accelerating growth in 2026.”

Segments

Medical Devices sales increased 12.3% on a reported basis and 10.4% on an organic basis to $5.68 billion.

Sales growth in the quarter was led by double-digit growth in electrophysiology, heart failure, diabetes care, ...